These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3499277)

  • 1. Amelioration of murine lupus nephritis by dimethylsulfoxide.
    Milner LS; de Chadarévian JP; Goodyer PR; Mills M; Kaplan BS
    Clin Immunol Immunopathol; 1987 Nov; 45(2):259-67. PubMed ID: 3499277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New immunosuppresor strategies in the treatment of murine lupus nephritis.
    Alperovich G; Rama I; Lloberas N; Franquesa M; Poveda R; Gomà M; Herrero-Fresneda I; Cruzado JM; Bolaños N; Carrera M; Grinyó JM; Torras J
    Lupus; 2007; 16(1):18-24. PubMed ID: 17283580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific increases in urinary excretion of anti-DNA antibodies in lupus mice induced by lysozyme administration: further evidence for DNA-anti-DNA immune complexes in the pathogenesis of nephritis.
    Yamamoto T; Nagase M; Hishida A; Honda N
    Clin Exp Immunol; 1993 Jan; 91(1):115-20. PubMed ID: 8419071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of protein excretion by dimethyl sulfoxide in rats with passive Heymann nephritis.
    Lotan D; Kaplan BS; Fong JS; Goodyer PR; de Chadarevian JP
    Kidney Int; 1984 May; 25(5):778-88. PubMed ID: 6471664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine lupus nephritis. Effects of glucocorticoid on circulating and tissue-bound immunoreactants.
    Cavallo T; Graves K; Granholm NA
    Lab Invest; 1983 Oct; 49(4):476-81. PubMed ID: 6604840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephritogenicity of anti-proteoglycan antibodies in experimental murine lupus nephritis.
    Kashihara N; Makino H; Szekanecz Z; Waltenbaugh CR; Kanwar YS
    Lab Invest; 1992 Dec; 67(6):752-60. PubMed ID: 1460866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB/W F1 mice.
    Tao X; Fan F; Hoffmann V; Longo NS; Lipsky PE
    Arthritis Res Ther; 2006; 8(1):R24. PubMed ID: 16507125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice.
    Hasegawa K; Hayashi T
    Lupus; 2003; 12(11):838-45. PubMed ID: 14667100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nrf2-deficient female mice develop lupus-like autoimmune nephritis.
    Yoh K; Itoh K; Enomoto A; Hirayama A; Yamaguchi N; Kobayashi M; Morito N; Koyama A; Yamamoto M; Takahashi S
    Kidney Int; 2001 Oct; 60(4):1343-53. PubMed ID: 11576348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Composition of immune deposits present in glomeruli of NZB/W F1 mice.
    Sugisaki T; Takase S
    Clin Immunol Immunopathol; 1991 Dec; 61(3):296-308. PubMed ID: 1934620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of dimethyl sulfoxide and nonsteroidal anti-inflammatory agents in passive Heymann's nephritis.
    Kaplan BS; Milner LS; Lotan D; Mills M; Goodyer PR; Fong JS
    J Lab Clin Med; 1986 May; 107(5):425-30. PubMed ID: 2939160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of autoimmune disease in NZB/W F1 mice by treatment with the novel immunomodulator BTS 63155.
    Appleby P; Telford G; Naylor GB
    Clin Exp Immunol; 1993 Sep; 93(3):313-7. PubMed ID: 8370159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lupus nephritis in autoimmune-prone NZB x NZW F1 mice and mechanisms of transition of the glomerular lesions.
    Tokado H; Yumura W; Shiota J; Hirose S; Sato H; Shirai T
    Acta Pathol Jpn; 1991 Jan; 41(1):1-11. PubMed ID: 2031455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine lupus nephritis: effects of cyclophosphamide on circulating and tissue bound immunoreactants.
    Cavallo T; Graves K; Granholm NA
    Clin Exp Immunol; 1984 Jan; 55(1):67-73. PubMed ID: 6607142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathology of lupus-like nephritis in Dnase1-deficient mice in comparison to NZB/W F1 mice.
    Jacob M; Napirei M; Ricken A; Dixkens C; Mannherz HG
    Lupus; 2002; 11(8):514-27. PubMed ID: 12220106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed lupus onset in (NZB x NZW)F1 mice expressing a human C-reactive protein transgene.
    Szalai AJ; Weaver CT; McCrory MA; van Ginkel FW; Reiman RM; Kearney JF; Marion TN; Volanakis JE
    Arthritis Rheum; 2003 Jun; 48(6):1602-11. PubMed ID: 12794828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid.
    Yung S; Zhang Q; Zhang CZ; Chan KW; Lui SL; Chan TM
    Arthritis Rheum; 2009 Jul; 60(7):2071-82. PubMed ID: 19565476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of E6060 [4-{5-[7-fluoro-4-(trifluoromethyl)benzo[b]furan-2-yl]-1H-2-pyrrolyl}benzoic acid], a novel subtype-selective retinoid, on lupus-like nephritis in female (NZBxNZW)F1 mice.
    Yamauchi T; Ishibashi A; Shikata K; Tokuhara N; Seino K; Kobayashi S; Nagai M
    J Pharmacol Exp Ther; 2005 Mar; 312(3):938-44. PubMed ID: 15615868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Laboratory and morphologic parameters in patients with lupus nephritis].
    Rasković S; Bogić M; Perić-Popadić A; Stefanović L; Arandjelović S; Jovicić Z; Bolpacić J; Tomić-Spirić V
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():38-41. PubMed ID: 12583312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristic immunohistochemical and ultrastructural glomerular lesions in Nude mice.
    Pelletier M; Hinglais N; Bach JF
    Lab Invest; 1975 Mar; 32(3):388-96. PubMed ID: 1091780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.